Clinical Trial Detail

NCT ID NCT03015896
Title Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Kami Maddocks
Indications

Hodgkin's lymphoma, lymphocytic-histiocytic predominance

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

mantle cell lymphoma

Burkitt lymphoma

lymphoplasmacytic lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Hodgkin's lymphoma

Therapies

Lenalidomide + Nivolumab

Age Groups: adult senior

No variant requirements are available.